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Abstract. Anemia is a common condition in HIV-infected children; however, its pathophysiology and the contribution
of frequent causes of anemia such as iron deficiency (ID) and malaria are poorly understood. We carried out an ancillary
studyon the effect ofHIVon anemia as part of a case–control studyon risk factors of anemia amongMozambican children
aged 1–59 months with documented HIV status. Of them, 390 children were admitted to the hospital with anemia
(hemoglobin [Hb] < 11 g/dL), whereas 272 children without anemia (Hb ³ 11 g/dL) were recruited in the community. We
assessed differences by HIV status in the presentation of anemia etiological factors and the effect of HIV infection on the
association of each factor with anemia. Among the 99 HIV-infected and 563 uninfected children included, HIV-infected
anemic children had an increased risk of undernutrition (P < 0.0001), Epstein–Barr virus infection (P < 0.0001), bacteremia
(P=0.0060), adecreased riskofmalaria (P<0.0001), andasimilar risk of ID (P=0.7371) comparedwith anemic-uninfected
children. HIV-infected children were significantly less likely to have anemia associated with Plasmodium falciparum
hyperparasitemia (P = 0.0444) and had a lower prevalence of parasitemia in the bone marrow (BM) (P < 0.0001) than
anemic-uninfected children. Levels of BM erythropoiesis and dyserythropoiesis were comparable between groups.
These findings suggest that the pathophysiology of anemia among HIV-infected malaria-exposed children is not related
to HIV-specific effects. For unclear reasons, HIV-infected children had reduced risk of malaria infection, whereas ID
prevalence was comparable in HIV-infected and uninfected children, suggesting that iron supplementation recom-
mendations should not be different in HIV-infected children.
INTRODUCTION
Anemia is a frequent complication of HIV infection, associ-
atedwithdiseaseprogression.1BothanemiaandHIV infection
are frequent in sub-Saharan Africa, where other infections and
malnutrition are also prevalent.1 In high-infectious pressure
settings, the diagnosis of anemia and its management is
hampered because of the multifactorial etiology of anemia.2
The pathophysiology of HIV-associated anemia in malaria-
endemic areas is not entirely understood, especially in chil-
dren.1 Studies among HIV-infected children using bone
marrow (BM) samples are scarce because of the lack of ex-
pertise, especially in low-income settings in carrying out BM
examination, which is the gold standard to assess the iron
status and theonly accurateway to analyze it.2However,most
studies using BM examination are retrospective or case re-
ports of small size with no control group, which prevents
having accurate information on the main contributors to ane-
mia inHIV-infected children.1,3–5 For instance, it is unclear how
much frequent causes of anemia, such as iron deficiency (ID)
and malaria, contribute to anemia of HIV-infected children.
Similarly, data on whether HIV infection modifies the risk of
anemia associated with some etiologic factors like ID or mal-
nutrition are limited.1,6,7
Therapeutic alternatives to manage anemia among HIV-
infected patients are limited. Subcutaneous erythropoietin
(EPO) is not easily accessible and affordable in low-income
countries. In addition, iron supplementation to HIV-infected
individuals remains controversial because of the lack of
evidence on the contribution of ID to HIV-related anemia and
the fear of harmful effects of iron supplementation in malaria-
endemic areas.1,8 As a consequence, most HIV-infected
children in low-income countries present some degree of
anemia.
As part of a case–control study on the etiology of anemia
among Mozambican children aged 1–59 months, we con-
ducted a secondary analysis with the goal of contributing to
improving the management and prevention of anemia in HIV-
infected children and the objectives of 1) assessing the as-
sociation between HIV status and anemia-related variables
among anemic children, 2) describing the pathophysiology of
anemia in HIV-infected children, and 3) analyzing the effect
modifier of HIV status on the risk of anemia associated with
frequent etiologic factors of anemia.
MATERIALS AND METHODS
Studysite.Thestudywascarriedout at theManhiçaDistrict
Hospital (MDH) and the Centro de Investigação em Saúde de
Manhiça (CISM), Maputo Province, in southern Mozambique
between October 2008 and August 2010. Since 1996, the
CISM runs a continuous demographic surveillance system
(DSS) that covered 130,351 inhabitants at the time of the
study. The CISM study area has been described in detail
elsewhere.9 During the study, HIV prevalence in adults (18–47
years of age) and children (£ 11 years old) was 38% and 1%,
respectively.10 The risk of mother-to-child HIV transmission in
the first month of life and at 1 year of age was 9% and 27%,
respectively.11 Most HIV-infected children had advanced
disease at the time of diagnosis.12 Clinical management of
HIV-infected children followed WHO guidelines at the time,
namely, starting antiretroviral treatment (ART) in infancy and
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following theWHOcriteria for children aged>1 year.13Malaria
transmission in thearea,mainly due toPlasmodium falciparum
(Pf), was perennial, with some seasonality. Community-based
prevalence of anemia (hemoglobin [Hb] < 11 g/dL) in children
younger than 5 years in Manhiça was 91% (C. Moraleda,
personal communication). G6PD deficiency prevalence was
around 9%, α-thalassemia (a-/a-) was about 15%, and sickle
cell disease and β-thalassemia were both less than 1%.14
Study participants and procedures. This was an ancillary
study within a case–control study on etiologic factors of
anemia in children aged 1–59 months.14 In brief, cases were
children attending the MDH emergency department between
October 2008 and August 2010 with anemia defined as an Hb
concentration < 11 g/dL in capillary samples,15 determined by
HemoCue® HB 201+system (Änghelom, Sweden), and with-
out a history of blood transfusion in the preceding 4 weeks.
Controls were children of the same age randomly selected
from the DSS who were visited at the community by study
personnel. Their Hb level was measured at home, and those
children with an Hb level ³ 11 g/dL were invited to attend the
MDH for a study visit. At study entry, a standardized ques-
tionnaire on clinical and demographic information was ad-
ministered to cases and controls, and capillary and venous
blood samples were collected. Urine and stool samples were
also collected when provided. Biological samples were pro-
cessed at the CISM laboratory. Some samples were shipped
to Barcelona, Spain, for further analysis. Bone marrow aspi-
ration was performed under conscious sedation and only in
anemic children (cases) ³3months of agewithout anymedical
contraindication or any risk at the discretion of the responsible
clinician. Study children were offered voluntary HIV counsel-
ing and testing. Only children with available HIV-positive or
negative test results orwith previouslydocumentedHIV status
were included in this analysis (see Figure 1). During the
conduct of the study and following national guidelines, HIV
status was assessed using the Determine HIV-1/2 Rapid Test
(Abbott Laboratories, Abbott Park, IL), and positive results
were confirmed by the Uni-Gold Rapid Test (Trinity Biotech
Co., Wicklow, Ireland). HIV infection was confirmed using the
HIV-1 DNA-PCR kit (Roche Molecular Systems, Branchburg,
NJ) in children with discordant results and in those aged
<18monthswhowerepositivebybothHIV rapid tests. All HIV-
infected children whose HIV status was unknown before re-
cruitment were further assessed at the HIV outpatient clinic.
Study definitions are summarized in Supplemental Table S1.
Laboratory methods. Blood counts other than Hb mea-
surements were performed using a Sysmex analyzer KX21N
and later an XT-2000i (Sysmex Long Grove, IL). Reticulocyte
counts were estimated by microscopy on cresyl blue-stained
blood smears.Plasmodium falciparum infectionwas identified
by microscopy in thick and thin Giemsa-stained blood films.
Plasmodium falciparum–specific real-time quantitative PCR
(qPCR) was performed on microscopically negative samples
at theHospital Clinic of Barcelona, Spain. Blood cultures were
performedonanautomated system (BACTEC®9050;Becton-
Dickinson, Franklin Lake, NJ). Epstein–Barr virus (EBV) and
parvovirus B19 (PV-B19) were detected by qPCR using the
Artus EBV RG PCR and the Artus Parvo B19 RG PCR kits
(QIAGEN), respectively. Epstein–Barr virus serology was
performed using the kits Merifluor® EBV anti-antigen capsid
virus (VCA) IgM IFA (Meridian Bioscience, Cincinnati, OH) and
CaptiaTM EBV VCA IgG (Trinity Biotech, Wicklow, Ireland).
Epstein–Barr virus testswere performed at theHospital Clı́nic,
Barcelona, Spain. Stool parasites were examined by micros-
copy using the merthiolate–iodine–formalin concentrations
method.16 Albumin, prealbumin, and C-reactive protein (CRP)
were measured in plasma using an ADVIA 2400 analyzer
(Siemens Healthcare, Spain), and folic acid, vitamin B12, and
FIGURE 1. Study flowchart. *It was not possible to perform all the procedures in each bonemarrow (BW) samples because of low quantity and/or
technical problems. The number of samples with the different results available was included in the corresponding table.
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ferritin were determined with an ADVIA Centaur (Siemens
Healthcare). Plasma-soluble transferrin receptors were
determined using a BN-II nephelometer (Dade-Siemens
Healthcare), vitamin A was determined by reversed-phase
high-performance liquid chromatography, and EPO was
quantified using the Quantikine human EPO immune-analysis
kit (R&D Systems). Bone marrow smears were stained by the
Perls’ Prussian blue method, and the BM iron content was
measured semi-quantitatively by the amount of blue-stained
hemosiderin pearls. Asexual parasitemia in BMwas estimated
as the percentage of infected red blood cells (iRBCs) in 1,000
RBCs, and gametocytes were counted in 100 fields. Hemo-
zoin content was assessed in BM macroscopic cell aggre-
gates, which were composed of stromal and parenchymal
cells and were needed for an optimal BM smear examination.
Hemozoin was detected by light microscopy as coarse brown
granular material with birefringence under polarized light.17
Erythropoiesis was assessed by three methods, namely,
morphological quantification, BM flow cytometric analysis,
and transcriptional score (Supplemental Table S1) (Achtman
et al., manuscript in preparation). Biochemistry and BM tests
were analyzed in the Hospital Clinic in Spain, whereas eryth-
ropoiesis analysis was performed at the Walter and Eliza Hall
Institute for Medical Research, Victoria, Australia.
Statistical analysis. Data were double entered using
MicrosoftVisual FoxPro5.0 (MicrosoftCorp.), andanalyseswere
performed using Stata/SE 14.0 for Mac (64-bit Intel) (StataCorp.
2015: Release 14. College Station, TX: StataCorp LP). Differ-
ences by HIV status in the presentation of anemia etiological
factors were assessed only in the group of anemic children by
logistic regression with Firth’s penalized likelihood, except for
the reticulocyte production index and BM measures of erythro-
poiesis, which were analyzed by linear regression (flow cytom-
etry in log scale). Logistic regression models with Firth’s
penalized likelihood and 95%CIs based on the Profile penalized
log likelihoodwere estimated to assess the impact of HIV on the
associationof eachpotential etiological factorwith anemia using
data from anemic and non-anemic children.18 Factor-specific
multivariable models were estimated using the factor, HIV, and
its interaction as independent variables. The modification of the
factor-specific association with anemia (interaction/effect mod-
ifier) was assessed by the odds ratio (OR) corresponding to the
interaction coefficient, that is, the ratio and 95% CI of the OR
(ROR) among HIV-infected children over the OR among HIV-
negative children.
Fractional polynomial analysis was used to compare the
relationship among plasma EPO and Hb concentrations
among the HIV-infected and uninfected children using the
estimated equation:





where “HIVstatus” is an indicator variable that equals 0 or 1 for
HIV-uninfected or HIV-infected children, respectively.
Ethics. The protocol of the case–control study was ap-
proved by the National Mozambican Ethics Committee and
the Hospital Clı́nic of Barcelona Ethics Review Committee.
The parents/guardians of all children included in the study
provided written informed consent after being informed of the
goals, procedures, benefits, and risks of taking a BM sample
from their child. No financial or material inducement for
participationwasoffered. Voluntary counseling and testing for
HIV were provided to all study participants at the enrolment of
the case–control study. The child was tested for HIV only after
consent was obtained. Permission for further analyses related
to the study was included in the informed consent form.
RESULTS
Study population. Demographic and clinical features of
study children are shown in Table 1. In the overarching
case–control study, 443 anemic children were recruited as
cases and 289 non-anemic children as community controls.
Of them, 662 (90%) children had an HIV result and were in-
cluded in this analysis, with 563 being (85%) HIV uninfected
(297 [53%] cases and 266 [47%] controls) and 99 (15%) HIV
infected (93 [94%] cases and six [6%] controls). Four (1%)
children had an indeterminate HIV test result; in 54 (7%) chil-
dren, the parents refused to perform the HIV test, and in 12
(2%) children, the sample was not adequate (see Figure 1).
HIV status and anemia-related variables among anemic
children. Association between HIV infection and anemia-
related variables among anemic children is summarized in
Table 2. The risks of having a positive EBV viral load and EBV
reactivation, bacteremia, albumin deficiency, and moderate
and severemalnutrition (see definitions in Supplemental Table
S1) were statistically significantly higher among anemic HIV-
infected children than among anemic uninfected children. On
the other hand, the risks of having Pf infection and clinical
malaria were lower among anemic HIV-infected than un-
infected anemic children (Table 2). HIV-infected anemic chil-
drenalsohada lowerprevalenceofPfparasitemia,gametocytes,
and hemozoin in BM than anemic uninfected children. However,
the prevalence of malaria gametocytes or hemozoin in BM
among childrenwithoutPf in peripheral bloodwas similar in HIV-
infected and uninfected children (Table 2). No statistically sig-
nificant associations between having HIV infection and iron,
vitamin A or vitamin B12 deficiencies, or intestinal parasitic in-
fections were found (Table 2). Among HIV-infected patients, two
children had parvovirus infection; in both of them, RBC precur-
sors were diminished in the BM without showing the character-
istic gigantic proerythroblasts.
HIV status andmarkers of anemia pathophysiology. The
association of HIV infection with markers of the main mech-
anisms of anemia pathophysiology, namely, blood loss, RBC
destruction, andchanges in erythropoiesis,were investigated.
Among anemic children, those with HIV infection had fewer
erythroid precursors by flow cytometry than uninfected chil-
dren (1.6% versus 2.4%, [P = 0.0227]), but these differences
were not statistically significant after adjusting for Pf infection
(P = 0.2748) (Table 3). Hemolysis was less frequent among
HIV-infected children than among uninfected children (6/65
[9%] versus 7/246 [29%], P = 0.0374). The frequency of dys-
erythropoiesis was similar between HIV-infected and un-
infected children (27/46 [59%] versus 103/144 [72%], P =
0.3923) (Table 3). The proportion of participants with elevated
EPO was also similar among HIV-infected and uninfected
children in the unadjusted analysis (P = 0.3418), but after
adjusting for Pf infection, the proportion was significantly
higher inHIV-infected children than uninfected children (69/88
[78%] versus 215/294 [73%]; P = 0.0434) (Table 3). Never-
theless, in the regression analysis, EPO synthesis in response
to anemia was not significantly different among the two
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groups of children. No differences were observed either for
HIV status (P = 0.3236) or HIV infection with Hb level in-
teraction (P = 0.2424) (Figure 2).
Effect of HIV infection on the etiology of anemia. The
effectmodifier of HIV infection on the factors related to anemia
is shown in Table 4. We did not observe an interaction of HIV
with the likelihood of anemia in the presence of positive EBV
viral load, bacteremia, albumin deficiency, and malnutrition.
The distribution of studied variables and the presence of
anemia by HIV groups are shown in Supplemental Table S2.
The association of hyperparasitemic Pf infection with anemia
among HIV-infected children was 67.5 times lower (1/effect of
modification) than that among uninfected children (ROR: 0.02;
95%CI: 0.00, 0.90; P=0.0444). Thus, for every case of anemia
among HIV-infected children with hyperparasitemic Pf in-
fection, 68 cases of hyperparasitemic Pf infection among
anemic HIV-uninfected children would be expected.
The association among ID (assessed by the ratio of soluble
transferrin receptor to log ferritin [TfR-F] index) and ane-
mia among HIV-infected children was 15.8 times lower
TABLE 1






93 (94) 99 (100)
Age (months)†
17.83 (18.23) [6]




53 (57) 55 (56) 0.4020k
Female
4 (67)
40 (43) 44 (44)
Total
6 (100)
93 (100) 99 (100)
Fever§
0/6 (0%)
80/93 (86%) 80/99 (81%) < 0.0001k
Hemoglobin†
11.40 (0.17) [6]
7.55 (1.94) [93] 7.79 (2.10) [99] < 0.0001‡
Hemoglobin < 7 g/dL§
0/6 (0%)
33/93 (35%) 33/99 (33) 0.1744k
CRP (mg/dL)†
0.21 (0.27) [5]
8.99 (8.64) [87] 8.52 (8.63) [92] 0.0262‡
HIV-infected status known before
study§ 1/6 (17%)
43/93 (46%) 44/99 (44) 0.2221k
Cotrimoxazole prophylaxis,§ n (%) No 0 (0) 27 (29) 27 (27) 0.2260k
Yes 0 (0) 11 (12) 11 (11)
NA 6 (100) 55 (59) 61 (62)
Highly active antiretroviral therapy
treatment,§ n (%)
No 0 (0) 70 (75) 70 (71) –
Yes 0 (0) 9 (10) 9 (9)
NA 6 (100) 14 (15) 20 (20)
HIV viral load copies/mL,§ n (%) < 10{ 0 (0) 14 (15) 14 (14) 0.0009k
³ 10{ 1 (17) 64 (69) 65 (66)
Undetectable 2 (33) 12 (13) 14 (14)
NA 3 (50) 3 (3) 6 (6)
HIV-negative, n (%)
266 (47)
297 (53) 563 (100)
Age (months)†
27.37 (18.62) [266]




173 (58) 294 (52) 0.0025{
Female
145 (55)
124 (42) 269 (48)
Total
266 (100)
297 (100) 563 (100)
Fever§
1/266 (0%)
262/297 (88%) 263/563 (47%) < 0.0001{
Hemoglobin†
11.67 (0.76) [266]
8.02 (1.96) [297] 9.74 (2.37) [563] < 0.0001‡
Hemoglobin < 7 g/dL§
0/266 (0%)
84/297 (28%) 84/563 (15%) < 0.0001{
CRP (mg/dL)†
0.38 (0.95) [262]
8.34 (7.75) [293] 4.58 (6.92) [555] < 0.0001‡
CRP = C-reactive protein; NA = not available (missing information). Bold figures: statistically significant results.
* Because it was not possible to obtain the need amount of blood in all the children, several analyses were not performed in some of them, so the denominator was not always as the total N.
†Arithmetic mean (SD) (n).
‡ t-test.
§ n (column percentage).
kFisher’s exact test.
{Chi-squared test.
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(1/interaction) than that among uninfected children. This dif-
ference is borderline significant at the 0.05 level (ROR: 0.063;
95% CI: 0.003, 1.248; P-value: 0.0696). The latter indicates
that for every case of anemia among HIV-infected children
with ID, 16 cases of anemia among uninfected childrenwith ID
would be expected. By contrast, among HIV-infected chil-
dren, the odds of anemia in those with ID (by BM iron content)
were nonsignificantly lower than those among those without
ID (OR: 0.21; 95% CI: 0.01, 4.00; P = 0.2971).
DISCUSSION
To our knowledge, this is the widest study on the patho-
physiology of anemia in HIV-infected children exposed to
TABLE 2
Differences according to HIV status in the presentation of variables related to anemia among anemic children
Variable
HIV*
Odds ratio (95% CI) P-valueNegative Positive
ID by BM† 101/127 (80%) 31/40 (78%) 0.87 (0.37,2.01) 0.7371‡
ID by TfR-F index by C-reactive protein* 184/262 (70%) 47/72 (65%) 0.79 (0.46,1.37) 0.4064†
Folate deficiency* 0/261 (0%) 0/72 (0%) 3.61 (0.07, 183.35) 0.5222†
Vitamin A deficiency* 205/294 (70%) 59/88 (67%) 0.88 (0.53, 1.46) 0.6159†
Vitamin B12 deficiency* 50/283 (18%) 11/80 (14%) 0.77 (0.38, 1.53) 0.4496†
Albumin deficiency* 104/293 (35%) 53/87 (61%) 2.81 (1.72, 4.59) < 0.0001†
Prealbumin deficiency* 265/292 (91%) 77/86 (90%) 0.84 (0.39, 1.84) 0.6720†
Wasting (WHZ < −2SD)* 66/293 (23%) 56/93 (60%) 5.15 (3.14, 8.46) < 0.0001†
Stunting (HAZ < −2SD)* 77/293 (26%) 52/93 (56%) 3.53 (2.18, 5.73) < 0.0001†
Underweight (WAZ < −2SD)* 114/297 (38%) 67/93 (72%) 4.08 (2.46, 6.77) < 0.0001†
Severe wasting (WHZ < −3SD)* 28/293 (10%) 39/93 (42%) 6.75 (3.85, 11.86) < 0.0001†
Severe stunting (HAZ < −3SD)* 19/293 (6%) 35/93 (38%) 8.54 (4.59, 15.89) < 0.0001†
Severe underweight (WAZ < −3SD)* 56/297 (19%) 53/93 (57%) 5.65 (3.42, 9.31) < 0.0001†
Parvovirus B19 infection* 23/297 (8%) 2/93 (2%) 0.32 (0.08, 1.20) 0.0912†
EBV viral load positive* 61/296 (21%) 42/93 (45%) 3.16 (1.93, 5.18) < 0.0001†
Acute EBV infection* 14/284 (5%) 8/85 (9%) 2.05 (0.85, 4.95) 0.1123†
EBV reactivation* 35/284 (12%) 26/85 (31%) 3.13 (1.76, 5.57) 0.0001†
Bacteremia* 17/287 (6%) 14/93 (15%) 2.82 (1.35, 5.91) 0.0060†
Clinical malaria 131/286 (46%) 18/90 (20%) 0.30 (0.17, 0.53) < 0.0001†
Pf infection* 137/286 (48%) 19/90 (21%) 0.30 (0.17, 0.51) < 0.0001†
Hyperparasitemic Pf* 27/286 (9%) 5/90 (6%) 0.61 (0.24, 1.57) 0.3018†
Submicroscopic Pf* 25/204 (12%) 10/83 (12%) 1.01 (0.47, 2.17) 0.9886†
Pf parasites in BM* 90/182 (49%) 10/58 (17%) 0.22 (0.11, 0.46) < 0.0001†
Hemozoin in BM* 80/144 (56%) 9/44 (20%) 0.21 (0.10, 0.47) 0.0001†
Gametocytes BM* 54/182 (30%) 6/57 (11%) 0.30 (0.12, 0.71) 0.0066†
Hemozoin in BM without Pf PI* 12/135 (9%) 3/43 (7%) 0.85 (0.25, 2.94) 0.8023†
Pf parasites in BM without Pf PI* 3/173 (2%) 1/56 (2%) 1.32 (0.19, 9.13) 0.7807†
Hookworm infection* 4/133 (3%) 1/51 (2%) 0.85 (0.13, 5.58) 0.8698†
BM= bonemarrow; EBV = Epstein–Barr virus; HAZ = height-for-age Z-score; ID = iron deficiency; Pf = Plasmodium falciparum; Pf PI = Plasmodium falciparum peripheral infection; TfR-F index =
ratio of soluble transferrin receptor to log ferritin; WAZ = weight-for-age Z score; WHZ = weight-for-height/length Z-score. Definitions of variables were included in Supplemental Table S1. Bold
figures: statistically significant results.
* Because it was not possible to obtain the need amount of blood in all the children, several analyses were not performed in some of them, so the denominator was not always as the total N.
† n (column percentage).
‡ Logistic regression with Firth’s penalized likelihood.
TABLE 3
Distribution of different markers of pathophysiological mechanisms of anemia among anemic children according to HIV status
Pathophysiological marker HIV-negative* HIV-positive* P-value P-value (adjusted for Plasmodium falciparum. infection)
Blood loss
Blood loss in feces† 3/133 (2%) 3/51 (6%) 0.2012‡ 0.2198‡
Blood loss in urine† 1/297 (0%) 0/93 (0%) 0.9730‡ 0.7434‡
Hemolysis 71/246 (29%) 6/65 (9%) 0.0026‡ 0.0374‡
Erythropoietin responsea (> 20 U/L)† 215/294 (73%) 69/88 (78%) 0.3418‡ 0.0434‡
Red cell production failure
Dyserythropoiesis† 103/144 (72%) 27/46 (59%) 0.1018‡ 0.3923‡
Reticulocyte Production index < 2† 204/215 (95%) 66/69 (96%) 0.9158‡ 0.5657‡
% Erythroid cellsb (Morphology)§ (n) 29.71 (16.63) [150] 25.33 (13.30) [51] 0.0905k 0.8165{
%Erythroid cellsc (FlowCytometry)# (n) 2.35 (2.21) [147] 1.64 (1.57) [49] 0.0227k 0.2748{
Transcriptional scoreof erythropoiesis§ (n) 0.06 (0.25) [82] 0.06 (0.20) [18] 0.9611k 0.6589{
Bold figures: statistically significant results.
* Because it was not possible to obtain the need amount of blood in all the children, several analyses were not performed in some of them, so the denominator was not always as the total N. a:
Laboratory reference; b: No of cells/100 nucleated cells; c: % gated cells.
† n (column percentage).
‡ Logistic regression with Firth’s penalized likelihood.
§Arithmetic mean (SD) [n].
kStudent’s t-test.
{Linear regression.
#Geometric mean (SD) [n].
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malaria with BM examination. The findings show that BM
function, as indicated by the number of erythroid precursors,
was not different between anemic HIV-infected children
andanemic uninfected children. Similarly, the prevalence of ID
was not different among those groups. These observations
indicate that these two mechanisms of anemia—BM dys-
function and ID—are not playing a different role in the patho-
physiology of anemia in HIV-infected children compared with
uninfected children. Nevertheless, anemic HIV-infected chil-
dren had an increased risk of malnutrition, positive EBV viral
load and bacteremia, and a decreased risk of Pf infection.
However, anemia associated with these conditions was not
modified by HIV infection. Moreover, HIV-infected children
had a lower risk of having anemia related to hyperparasitemia
than uninfected children.
The pathogenesis of anemia in HIV-infected children is not
completely understood. Previous studies reported that in-
flammation and the direct virus effect on the BM are the main
pathophysiologic mechanisms of anemia.19 Bone marrow
abnormalities are frequently observed in HIV-infected pa-
tients; however, these features are nonspecific and often as-
sociated with opportunistic infections.20 Our findings do not
support previous reports suggesting that red cell production
failure is an essential cause of anemia in HIV-infected children
as compared with anemic uninfected children.20 In this study,
the percentage of the red cell lineage in the BM was similar
among the two anemic groups after adjusting for Pf infection,
suggesting that the increased prevalence of Pf infection in the
HIV-uninfected group could induce an increased red cell
production in the BM—which has already been suggested—
confounding the difference observed in the unadjusted analysis21
(Achtman et al., manuscript in preparation).
Unlike previous observations, in this study, we did not ob-
serve a difference in ID prevalence, defined by the BM iron
content between anemic HIV-infected and anemic HIV-
uninfected groups.6 This discrepancy may be explained by
the use or not of ferritin levels in the definitions of ID.22,23
Serum ferritin is an acute-phase protein that rises during in-
flammation, and its level is frequently increased in HIV pa-
tients, not reflecting iron stores.19,22,23 Besides BM content,
we determined iron status using an ID definition based on the
TfR-F index adjusted by the CRP. The effect modifier of HIV in
the risk of anemia due to ID based on the TfR-F index was
borderline significant, suggesting that someof the parameters
used in this index may be affected by the inflammation asso-
ciated with HIV infection. The results also show that unlike in
uninfected children, there is no difference in the risk of anemia
among HIV-infected children with or without ID. This absence
of difference might be explained by other more important
factors contributing to anemia among HIV-infected children
(such as albumin deficiency). Importantly, the prevalence of
ID—defined by the BM iron content—was common among
HIV-infected children (78%), with prevalence similar to that in
uninfected children (80%). In settings with high-infectious
pressure, iron supplementation to treat and prevent ID is
controversial because of reports on the association of high
iron levels with worse clinical prognoses, and of iron supple-
mentation and increased risk of malaria episodes.8,24 The
WHO has published new guidelines on ID prevention in
malaria-endemic areas recommending universal iron supple-
mentation; however, these guidelines do not contain specific
recommendations for HIV-infected individuals.25 Given the
high prevalence of ID observed, and given that iron supple-
mentation has shown to improve Hb levels, reduce anemia
prevalence, and increase CD4 percentage, iron provision to
HIV-infected children should be considered to prevent anemia
in this vulnerable population.8
In this study, HIV-infected children had a reduced risk of Pf
infection and clinical malaria and lower prevalence of Pf par-
asites, gametocytes, and hemozoin in BM. Unlike adults, in
whom HIV infection is a risk factor for severe malaria, in chil-
dren, the effect of HIV on malaria risk is less clear, possibly
FIGURE 2. Erythropoietin levels in response to hemoglobin concentrations in HIV-infected and HIV-uninfected children.
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because of their immunologically naive status regarding Pf
parasites, and is less studied.7 Previous studies reported a
lower risk of Pf infection in HIV-infected children.26,27 How-
ever, in other studies, no differences in the prevalence of
parasitemia by HIV status were reported, although the in-
creasing frequency of clinical malaria with the severity of im-
munosuppression was observed.28–31 One explanation for
these discrepancies between cross-sectional studies in ad-
mitted patients and cohort studies of HIV-infected patients
might be thatHIV-infectedchildren consultmore frequently for
other pathologies related toHIV infection, such aspneumonia,
diarrhea, or bacteremia, and less for malaria (competing risk
theory).26–30,32,33 This hypothesis is supported by the obser-
vation that the prevalence of hemozoin or gametocytes in the
BM among children without Pf peripheral parasitemia—a sign
of past malaria infection—was similar between HIV-infected
and uninfected children.34 The antimalarial effect of cotri-
moxazole prophylaxis may also be associated with reduced
risk of malaria in the HIV-infected group,35 although the ad-
herence to this prophylaxis was very poor in the study
population, and less than half of the HIV-infected patients
knew their status before the recruitment into the study
(Table 1). A limitation of the study is that the information of the
children who were on cotrimoxazole prophylaxis relied on the
response of the caregivers; in addition, this information was
not available in 62% of the cases. On the other hand, it is also
possible that some infants not infected but HIV-exposed
could be on cotrimoxazole prophylaxis in the HIV-uninfected
group. Importantly, HIV-infected children had a lower risk of
having anemia related to Pf hyperparasitemia than HIV-
uninfected children. This may be explained by the fact that in
HIV-infected patients, anemia due to other etiological factors
is already present before malaria infection occurs, decreasing
the relative contribution of malaria hyperparasitemia as a
cause of anemia in this group.
Unlike HIV-infected adults, in whom EPO levels do not
correlate with Hb levels,36 we found that EPO production was
similar in HIV-infected and uninfected children. Moreover, as
reported previously in African children, the proportion of HIV-
infected children with elevated EPO levels was higher than
TABLE 4
Association between clinical variables related to anemia and anemia adjusted for HIV and effect of modifier (interaction) of the HIV infection
Variable No of observations* Odds ratio of anemia (95% CI) P-value
Iron deficiency by TfR-F index by C-reactive protein 580 3.28 (2.27; 4.73) < 0.0001
Effect modifier 0.06 (0.00; 1.25) 0.0696
Parvovirus B19 infection 662 4.07 (1.58; 10.46) 0.0036
Effect modifier 0.09 (0.00; 2.31) 0.1447
EBV positive viral load 660 1.64 (1.05; 2.57) 0.0301
Effect modifier 6.53 (0.35; 123.51) 0.2107
Acute EBV infection 633 2.47 (0.91; 6.69) 0.0752
Effect modifier 0.58 (0.03; 13.14) 0.7303
EBV reactivation 633 1.36 (0.79; 2.35) 0.2665
Effect modifier 4.25 (0.22; 82.30) 0.3384
Wasting (WHZ < −2SD) 651 4.05 (2.32; 7.07) < 0.0001
Effect modifier 1.36 (0.20; 9.43) 0.7531
Stunting (HAZ < −2SD) 654 2.37 (1.52; 3.69) 0.0001
Effect modifier 6.94 (0.37; 131.02) 0.1964
Underweight (WAZ < −2SD) 659 4.96 (3.17; 7.77) < 0.0001
Effect modifier 1.88 (0.28; 12.76) 0.5169
Severe wasting (WHZ < −3SD) 651 3.18 (1.45; 6.96) 0.0039
Effect modifier 2.97 (0.15; 60.16) 0.4789
Severe stunting (HAZ < −3SD) 654 1.42 (0.69; 2.96) 0.3433
Effect modifier 5.54 (0.28; 110.96) 0.2628
Severe underweight (WAZ < −3SD) 659 4.71 (2.49; 8.91) < 0.0001
Effect modifier 1.03 (0.15; 7.29) 0.9772
Albumin deficiency 647 13.26 (6.84; 25.71) < 0.0001
Effect modifier 1.29 (0.06; 25.84) 0.8694
Prealbumin deficiency 643 18.19 (11.39; 29.05) < 0.0001
Effect modifier 0.63 (0.10; 3.87) 0.6160
Vitamin A deficiency 650 5.84 (4.05; 8.42) < 0.0001
Effect modifier 0.48 (0.09; 2.70) 0.4079
Vitamin B12 deficiency 617 0.85 (0.55; 1.32) 0.4767
Effect modifier 0.58 (0.08; 4.28) 0.5943
Bacteremia 650 4.83 (1.52; 15.42) 0.0078
Effect modifier 0.49 (0.02; 11.47) 0.6578
Pf. infection 648 11.67 (6.97; 19.55) < 0.0001
Effect modifier 0.30 (0.02; 5.89) 0.4308
Hyperparasitemic Pf 648 56.48 (3.43; 930.83) 0.0048
Effect modifier 0.015 (0.00; 0.90) 0.0444
Submicroscopic Pf 556 3.12 (1.52; 6.42) 0.0020
Effect modifier 0.60 (0.03; 12.39) 0.7378
Hookworm infection 332 0.45 (0.15; 1.40) 0.1682
Effect modifier 0.33 (0.01; 12.33) 0.5474
EBV = Epstein–Barr virus; HAZ = height-for-age Z-score; Pf = Plasmodium falciparum; TfR-F index = ratio of soluble transferrin receptor to log ferritin; WHZ = weight-for-height/length Z-score;
WAZ =weight-for-age Z score. Bold figures: effect modifier with level of significance. Each line shows the odds ratio of being anemic related to each variable adjusted by HIV infection and how this
odds ratio is modified by the presence of HIV (effect of modifier) in the case this effect was significant. For the calculation of the effect modifier, all the children with known HIV status (the cases
[anemicwith Hb < 11 g/dL] and the controls (non-anemicwith Hb g/day)] were included. The distribution of variables and anemiawithin HIV groups are in Supplemental Table S2. Eachmodel has an
odds ratio for HIV infection, but these data are not shown.
* Because it was not possible to obtain the need amount of blood in all the children, several analyses were not performed in some of them, so the denominator was not always as the total N.
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that of uninfected children.23 Further studies are needed to
determine whether the presence of anti-EPO antibodies or an
altered EPO responsiveness might play a role in the patho-
physiology of HIV-related anemia. The prevalence of hemo-
lysis was lower in HIV-infected children than that in the
uninfected group even after adjusting for Pf infection, sug-
gesting that the pathophysiology of anemia in HIV infection
does not have a relevant hemolytic component.
Protein–caloric malnutrition has been described as an eti-
ological factor for anemia, although the pathophysiologic
mechanismsare notwell understood.14,37 The adverse effects
of HIV infection on nutritional status have been widely re-
ported, which agrees with the increased risk of malnutrition
among HIV-infected children in this study.12 Nutritional sup-
port to HIV-infected patients to reduce malnutrition-related
anemia must be a priority because of its high prevalence, al-
thoughHIV infection did not increase the risk of anemia related
to malnutrition.
Parvovirus infection may cause chronic anemia, and anti-
bodies against this virus are reported to be more prevalent in
HIV-infected individuals than inHIV-uninfected populations.38
As in other reports, in this study, no differenceswere observed
in parvovirus infection prevalence between HIV-infected and
uninfected children.39 Epstein–Barr viral load positive and
reactivationweremore frequent amongHIV-infected children;
however, the risk of anemia associated with EBV infection did
not change by HIV status. Furthermore, EBV infection was not
independently associated with anemia, indicating that its
preventionmight not have an impact on anemia prevalence.14
The frequency of bacteremia is increased among HIV-
infected patients, which may be a cause of anemia and a
mediating factor of the effect of HIV on severe anemia.14 Ac-
cordingly, in this study, bacteremia wasmore frequent in HIV-
infected children than in uninfected children. However, HIV
infection did not modify the risk of anemia secondary to
bacteremia. The increased prevalence of bacteremia among
admitted HIV-infected children would justify the empirical
administration of antibiotics in the management of anemia in
settings where blood cultures are not available.
No information is reported on the association of helminthic
infections, commonly associated with anemia, and HIV in-
fection in children. In this study, although numberswere small,
no differences in the prevalence of hookworm infection be-
tween the two groups of children were observed.
The immune status of the HIV-infected children may influ-
ence the findings in the BM; asmost of the patientswere in the
early stages of the disease, theBMcould be less affected, and
differences among groups are less marked. Results of CD4
counts were not available because of limited access to this
analysis at the time of the study, and the clinical stage of the
children was not recorded, which is a limitation of the study.
However, nearly 70% of the HIV-infected children had high
viral loads, suggesting they were in advanced disease. Al-
though ART could affect the BM response—improving dis-
ease and HIV-related anemia or affecting erythropoiesis due
to drug toxicity—only 10%of the childrenwere on ART, so the
influence of this factor in the HIV-infected children is expected
to be limited in both ways. Another study limitation is that
some parents refused the HIV test for their children, in-
troducing a potential bias because these are likely to have
been infected. It is also important to notice that the observed
associations among the study variables and anemia among
HIV-infected children cannot be considered as the cause of
their anemia because of the case–control design of the study.
However, all study variables are known causes of anemia and
should be taken into account as a possible relevant cause of
anemia in this population, mainly those that have been asso-
ciated with HIV infection in this study.37,40–44 On the other
hand, inflammation has not been studied as an independent
etiology of anemia in this study, as it is very unspecific. C-
reactive proteinwas higher in the anemic and theHIV-infected
group (Table 1); however, the cause of the observed high CRP
levels could be related to several infections limiting the public
health implications of this observation. Therefore, the role of
anemia of inflammation in the physiopathology of anemia in
HIV-infected children should be considered. The potential
bias caused by rare events due to the small number of HIV-
infected controls had been mitigated by using the penalized
likelihood for estimating logistic regression models.18 Finally,
although this analysis is based on information collected sev-
eral years ago, unfortunately, these findings are still relevant to
guide policies to reduce the burden of anemia in HIV-infected
childrenexposed tomalaria, given the scarcity of interventions
focused on reducing this problem in this vulnerable group.
In summary, the pathophysiology of anemia among HIV-
infected malaria-exposed children does not seem to be
associated with a specific effect of the HIV infection. Never-
theless, other common causes of anemia, such as undernu-
trition or bacteremia, may play a role in the anemia etiology
in HIV-infected children because of the high prevalence of
these conditions. Iron deficiency prevalence was comparable
in HIV-infected and uninfected children, suggesting that iron
supplementation recommendations should not be different in
HIV-infected children.
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